Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported robust first quarter 2026 financial results highlighted by $10.3 million in net product revenue from the commercial launch of PALSONIFY, a treatment for acromegaly. The company has expanded its prescriber base and patient enrollment forms, gained significant reimbursement coverage, and achieved regulatory approval…